Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.51 |
| ▸ | PREP | P48147 | 1/20 | 0.47 |
| ▸ | ULK1 | O75385 | 5/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25307043 | 0.87 | PREP (0.45) | LOXL2PREPULK1GABRA5KDM1A | |
| SCHEMBL31055431 | 0.86 | ADORA2A (0.50) | PREPKDM1AHDAC1HDAC6LMNA | |
| SCHEMBL18030366 | 0.82 | LOXL2 (0.51) | LOXL2ULK1GABRA5MAPK14EPHX2 | |
| SCHEMBL31055454 | 0.79 | PREP (0.45) | PREPKDM1AHDAC1HDAC6EPHX2 | |
| SCHEMBL3299192 | 0.78 | HPGD (0.51) | PREPKDM1AHDAC1HDAC6HTT | |
| SCHEMBL2998198 | 0.77 | KDM4E (0.55) | PREPKDM1AHDAC1HDAC6LMNA | |
| SCHEMBL30315883 | 0.77 | KDM4E (0.55) | PREPKDM1AHDAC1HDAC6LMNA | |
| SCHEMBL31055445 | 0.76 | GAA (0.59) | PREPKDM1AHDAC1HDAC6LMNA | |
| SCHEMBL30469344 | 0.76 | LOXL2 (0.66) | LOXL2ULK1GABRA5SMN1; SMN2KDM4E | |
| SCHEMBL24358061 | 0.75 | LOXL2 (0.45) | LOXL2ULK1GABRA5MAPK14EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250042895-A1 | INHIBITORS OF ULK1 AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2025-02-06 | — | — | US | disclosed |
| WO-2023059786-A1 | INHIBITORS OF ULK1 AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042895-A1 | INHIBITORS OF ULK1 AND METHODS OF USE | ULK1, ULK2, ULK3 | LOXL2 2625/4885PREP 3726/4885ULK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.